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Abstract Autogenous bone grafting, used to repair bone
defects, is limited and the donor site can experience com-
plications. Compared to autogenous bone graft, artificial
bones have different porosity, which might make them
suitable alternatives to bone grafts. Here, two porous
biphasic calcium phosphate bone substitutes, namely
BiceraTM and TriositeTM, are used in an animal study and
clinical practice to find a suitable porosity for implantation.
BiceraTM and TriositeTM consist of 60 wt% hydroxyapatite
and 40 wt% b-tricalcium phosphate, with the porosity of
BiceraTM (82%) being higher than that of TriositeTM
(70%). In the animal study, the implantation procedure was
carried out on twenty-four female New Zealand rabbits.
12 weeks after implantation, the new bones were well
infiltrated into the BiceraTM and TriositeTM bone grafts. In
the clinical study, patients with comminuted fracture,
fracture nonunion, or arthrodesis were included in the study
of bone substitution with BiceraTM. 27 patients underwent
fracture fixation treatment. Bone healing of 22.22% (6/27)
of patients happened within 3 months after the surgery, and
that of 66.67% (18/27) of patients happened within
6 months. These results reveal that BiceraTM has good
incorporation with host bone, and that new bone is able to
grow within the porous structure, giving it high potential in
the treatment of bone defects.
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1 Introduction
Treatment for comminuted fracture is a challenging task.
This type of fracture usually occurs with osteoporosis or
major trauma. Comminuted fractures usually have bone
defects, which breakdown the bone structure and reduce
potential of bone healing. In order to promote bone healing,
bone substitute is often used to provide a scaffold for the
new bone to regenerate or to support the articular frag-
ments. Although autogenous bone grafting is favorable for
bone defect treatment, it still has some serious complica-
tions such as limited graft volume and donor site mor-
bidities [1, 2]. Therefore, the allograft and xenograft are
frequently used as an alternative treatment. In recent dec-
ades, a variety of artificial bone substitutes have been
developed for clinical use [3].
Synthetic calcium phosphates are commonly used in
bone substitutes [4]. Within the group of phosphates,
hydroxyapatite (HA) and tricalcium phosphate (TCP) are
the most common materials used for bone substitution [5].
HA has excellent biocompatibility with the bony environ-
ment; however, it is mostly used for surface coating on
metal implants due to its low solubility and brittle nature
[6]. TCP has the advantage of osteoconductivity, but it is
limited in clinical use due to its rapid degradation rate [7].
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Therefore, biphasic calcium phosphate (BCP) has been
used to overcome the disadvantages of HA and TCP. Since
BCP includes HA and TCP, it provides optimal dissolution
and good bioactivity, cell attachment, proliferation, and
differentiation for new bone regeneration [8].
Although previous studies have shown that bone sub-
stitute porosity plays a significant role in bone regenera-
tion, the optimal porosity for bone healing is not known
[9]. The present study thus investigates the most suit-
able biodegradable porous artificial bone using the rabbit
model and clinical trials. Two kinds of porous BCP bone
substitute are evaluated, namely BiceraTM and TriositeTM.
BiceraTM is composed of 60% HA and 40% TCP and has a
pore size of about 461.92 ± 90.66 lm. It is characterized
by interconnected pores with a porosity of 82.62 ± 0.02%.
TriositeTM has the same composition, but its pore size and
porosity are approximately 450 lm and 70%, respectively
(Table 1). The objective of the present study is to inves-
tigate the BiceraTM bone substitute for comminuted frac-
ture because of its potential to provide a highly porous and
interconnected structure for new bone regeneration.
Specifically, post-operative healing after treatment with
BCP bone substitute is demonstrated. The clinical out-
comes of 27 patients in a retrospective study on BCP bone
substitute are also described. Additionally, histological
confirmation of the incorporation of BiceraTM and Triosi-
teTM and the formation of new bone are evaluated using the
rabbit model with a femoral condyle cancellous bone
defect.
2 Materials and Methods
2.1 Materials
The bone substitutes used in the study are BiceraTM
(Wiltrom Ltd, Taiwan.) and TriositeTM (Zimmer Ltd.,
Swindon, UK). BiceraTM and TriositeTM are compossed of
BCP (60% HA and 40% TCP). Information on BiceraTM
and TriositeTM is presented in Table 1. BiceraTM has a
higher porosity and similar pore size compared to those of
TriositeTM. The interconnected pores of BiceraTM can act
like a guide for bone tissue growth. Both BCP bone sub-
stitutes used in this study are FDA-approved in the USA as
bone void filler.
2.2 Animal Study
The animal study was carried out using twenty-four female
New Zealand rabbits (20 weeks old, average weight of
approximately 3.0 kg) based on a protocol approved by the
Institutional Animal Experiment Committee of National
Taiwan University, Taipei, Taiwan.
The rabbits were anesthetized by an intramuscular injec-
tion of a mixture of Ketamin (0.5 ml/kg) and Comblene
(0.5 ml/kg). The bone graft substitutes (BiceraTM and Trio-
siteTM), 5 mm in diameter and 10 mm in length, were steril-
ized prior to implantation. A 2.5-cm skin incisionwasmade to
expose the lateral femoral condyle of the thigh. A bony defect
5 mm in diameter and 10 mm in depth was created on both
femurs by drilling using a stopper set designed for creating
critical size defects. The diameter and depth of the defectwere
measured using a sterilized ruler and a depth gauge, respec-
tively, to confirm the desired dimension. Bone substitute
(5 mm in diameter and 10 mm in length)was used to fill in the
defect site (Fig. 1). Finally, the endodermis, muscle tissue,
and surface skin were closed with sutures after implantation.
BiceraTM was implanted into all twenty-four left femurs.
TriositeTM was placed into twelve right femurs, with the
remaining twelve right femurs left cavernous as the empty
control. The femoral defects were evaluated at 4, 8, and
12 weeks following surgery.
Animals were sacrificed at 4, 8, and 12 weeks. Femur
samples were harvested at the designated time period and
fixed in 10% formalin for 24 h. For histological analysis,
specimens were embedded in polymethyl methacrylate.
These specimens were cut and aligned with the diametral
plane. The section was mounted on a slide and stained with
Masson-Goldner trichrome. After staining, muscle fiber
was red, collagen was blue, and voids were white. The
toluidine blue method was used to identify mineralized
bone. After staining with toluidine blue, mineralized bone
was blue. The sections were also collected for histomor-
phometric analysis.
2.3 Human Clinical Study
From June, 2011 to December, 2012, 27 patients with
comminuted fracture (scaphoid, tibia, humerus, clavicle,
femur, wrist, distal radius, or ankle) were treated with
BiceraTM. The artificial bone grafts were placed between
the broken bone (e.g., for a humeral shaft fracture) or at the
Table 1 Comparison of
BiceraTM and TriositeTM
BiceraTM TriositeTM
Composition Biphasic calcium phosphate Biphasic calcium phosphate
Porosity (%) 82.62 ± 0.02 70
Pore size (lm) 461.92 ± 90.66 450 ± 49
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Fig. 1 Implantation procedure a Exposure of lateral femoral condyle.
b Bony defect 5 mm in diameter and 10 mm in length was created in
both femurs using a surgical drill bit. c, d Diameter and depth of the
defect were measured. e, f Bone substitute 5 mm in diameter and
10 mm in length was filled into the defect site. SEM micrographs of
g, h BiceraTM and TriositeTM
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subcortical area to fill the space (e.g., for a tibial plateau
fracture). The amount of bone substitute depended on the
bone defect; up to 5 ml of BiceraTM was used intraopera-
tively. All procedures were performed at Far Eastern
Memorial Hospital, New Taipei City, Taiwan. This study
evaluated the radiographs monthly. Fracture healing or
bone fusion was defined as callus bridging with at least
three cortices in the radiographs. The duration from oper-
ation to fracture healing or bone fusion was recorded.
Inclusion criteria for patients were comminuted fractures,
nonunion, or arthrodesis of four limbs. Exclusion criteria
were an age below80 years and having concomitant diseases
that might be worsened by invasive treatment of the fracture,
such as a local tumor. Patients were also excluded if they had
a history of malignancy, infection, abnormal laboratory
finding, a liver function abnormality, or metabolic bone
disease. Patients that met the inclusion criteria were offered
the procedure with bone substitutes and informed consent
was obtained. The clinical study was approved by the
Research Ethics Review Committee (103053-E) of Far
Eastern Memorial Hospital, New Taipei City, Taiwan.
3 Results
3.1 Radiographic Evaluation in Animal Study
From Table 1 and scanning electron microscopy (SEM)
micrographs (Fig. 1), BiceraTM had superior intercon-
nected pore structure and higher porosity compared to
those of TriositeTM. The radiographs of implant sites at 4,
8, and 12 weeks after implantation showed that both bone
substitutes were well incorporated with surrounding bone
(Fig. 2). The defect of the lateral femoral condyle without
bone substitute was still empty. 12 weeks after implanta-
tion, both bone substitutes showed no significant
degradation.
3.2 Histological Examination in Animal Study
The optical micrographs of the femoral condyle specimen
are shown in Fig. 3. Four weeks after implantation, the
defects were surrounded by bone tissue. The amounts of
new bone that had formed in two bone substitute groups
Fig. 2 Rabbit femur condyle X-ray image. Defect without bone substitute was still an empty cavity. Both bone substitutes remained completely
intact, with no significant degradation observed 12 weeks after implantation (arrow implant site)
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were significantly higher than that for the empty control. In
the BiceraTM group, new bone had grown from the margin
of macropores toward the inside of the substitute, whereas
in the TriositeTM group, new bone formation occurred only
around the periphery. 8 weeks after implantation, although
the new bone grew in bone substitute groups, unlike in the
BiceraTM group, void spaces were not filled completely in
the TriositeTM group (Fig. 3). In the empty control group,
defects were surrounded by bone tissue but failed to form
any new bone. The porous structure of BiceraTM showed
some sign of degradation. New bone was also observed
inside the porous structure of BiceraTM. In the TriositeTM
group, the ingrowth of new bone occurred from the
periphery toward the center of the defect site. At 12 weeks
post-implantation, no fibrous tissue or inflammation
response was observed at any defect site. The empty con-
trol group revealed no sign of bone growth at any defect
site (Fig. 3). In Fig. 4, the area of new bone formation
occupied only 4% of the cavities in the empty control
group. The new bone formation occupied 14 and 12% of
Fig. 3 Histological image of rabbit femoral condyle tissue section. In
BiceraTM group, new bone (blue area) grew into porous structure of
bone substitute (black area). In TriositeTM group, there was an
obvious interface between bone substitute (black area) and host bone
(blue area) (SB surrounding bone, NB new bone, BC BiceraTM, TS


























Fig. 4 Percentage of new bone formation. 12 weeks after implanta-
tion, new bone formation occurred in up to 14% of total cavities in
BiceraTM. With TriositeTM, new bone formation occurred in 12% of
total cavities inside the material (*p B 0.05)
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the area in the BiceraTM and TriositeTM groups, respec-
tively. The two bone substitutes had similar bone formation
properties. From the statistical analysis, there was a sig-
nificant difference in new bone formation between the
BiceraTM and empty control groups at 8 and 12 weeks.
This indicates that BiceraTM had good osteoconductivity
and that its high porosity served as a good scaffold struc-
ture for new bone ingrowth.
3.3 Human Clinical Study
A total of 44 patients were recruited according to the
inclusion criteria. Fifteen patients were excluded: one had
an infection, one had mal-union, three had poor radiograph
quality, and ten had follow-up of less than 6 months. Of the
remaining 27 patients (Table 2), 14 were men and 13 were
women. The mean age was 44.22 years (range of
18–79 years). The numbers of revision fracture fixations,
comminuted fracture fixations, and arthrodeses were 3, 23,
and 1, respectively. Among the 27 patients, 6 patients had
healed within 3 months, 12 patients had healed in
4–6 months, 2 patients had healed in 7–12 months, and 2
patients had delayed healing (16 and 18 months). The
radiographs of patients who had bone union showed solid
union (Figs. 5 and 6), and no further revision surgeries
were needed. Of the five patients who failed to get bone
union, two patients had hypertrophic nonunion, two had
loss of reduction and further collapse, and one had radi-
olucent gaps in the final radiographs.
4 Discussion
The architecture of ceramic bone substitutes is the key to
creating an environment for osteogenic cell adhesion, prolif-
eration, and differentiation. BCP (BiceraTM and TriositeTM) is
Table 2 Patient information




1 26 F Scaphoid fracture O 16 16
2 56 M Tibial medial plateau fracture O 5 10
3 49 F Proximal humeral fracture O 3 4
4 62 F Clavicle fracture s/p ORIF, loss of reduction O 4 7
5 57 M Right proximal tibia fracture X 16
6 24 M Distal femur fracture O 18 18
7 30 M Humeral shaft fracture s/p ORIF, implant failure X 9
8 32 M Tibial plateau fracture O 2 18
9 46 F Bilateral wrist rheumatoid arthritis O 3 7
10 40 F Humeral shaft open fracture O 6 8
11 31 M Clavicle shaft fracture O 9 11
12 37 M Tibia plateau fracture O 8 18
13 79 F Distal radius fracture O 4 5
14 36 M Left tibia plateau fracture O 3 14
15 25 M Femur proximal shaft fracture X 15
16 32 M Clavicle fracture O 6 12
17 54 F Tibia plateau fracture O 4 14
18 33 F Distal radius fracture O 3 11
19 39 M Distal radius fracture O 4 12
20 70 F Distal femur periprosthetic fracture O 6 26
21 18 M Clavicle fracture O 5 8
22 27 M Femoral shaft fracture X 13
23 29 F Tibia plateau fracture O 5 15
24 48 M Ankle bimalleolar fracture O 3 4
25 66 F Distal radio-ulnar fracture O 6 8
26 74 F Proximal tibia fracture X 13
27 74 F Supracondylar femoral fracture O 6 13
ORIF open reduction and internal fixation, s/p status post
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composed of two components, namely HA and TCP, which
are the two most important calcium phosphate ceramics for
bone regeneration [5].HA resembles the inorganic component
of human bone and is considered as an osteoconductive and
bioactive ceramic [10]. TCP is gradually replaced by new
bone due to its bioresorbability [11]. BCP ceramics have a
longer degradation rate than that ofTCP and are stable enough
to provide bone formation for six months after implantation
[12]. We conducted the rabbit femoral defect experiment to
evaluate the effectiveness of the bone substitutes. The control
groups were an empty defect and a defect filled with the
commercial ceramic TriositeTM.
In order to simulate the repair of bone with bone sub-
stitutes, we defined a critical defect 5 mm in diameter and
10 mm in length, which was drilled at the bilateral femoral
condyles and filled with the same-size substitute. In this
study, there was only a slight amount of new bone for-
mation 12 weeks after implantation for the no treatment
control group. Both bone substitutes exhibited different
results based on radiographic and histological examination.
At 4 weeks post-implantation, new bone was found in the
macropores in BiceraTM, and bone mineralization was
found around the central area (Fig. 3). With TriositeTM,
new bone was discovered along the periphery, and there
Fig. 5 A 40-year-old women had left humeral shaft fracture. She underwent open reduction internal fixation and BiceraTM was filled into
fracture (comminuted fracture). Radiograph revealed fracture union 6 months after operation
Fig. 6 A 66-year-old women had right humeral shaft and neck fracture. She underwent open reduction internal fixation via a minimally invasive
technique and BiceraTM was filled into fracture. Radiograph revealed fracture union 6 months after operation
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were only small amounts of new bone in the central region.
8 weeks after implantation, new bone infiltrated from the
periphery toward the center for both bone substitutes. The
porous structure of the substitutes plays an important role
in osteoconductivity. At 12 weeks post-implantation, there
was no evidential degradation of the ceramics. Both sub-
stitutes maintained almost complete structure for new bone
ingrowth.
The primary goal of trauma treatment is the successful
union of the bone. In this study, for the 27 patients with the
bone substitute, bone fusion or union was evaluated based on
radiographs. Callus bridging with at least three cortices in the
post-operative radiographs was considered as bone fusion or
union. In addition to bone fusion or union, the general purpose
of fracture treatment is to stabilize the fracture and repair bone
in its original position. Nonunion and delayed union are
common complications of comminuted fracture and
arthrodesis [13]. Bone substitute is a great way to speed up the
healing process. In our preliminary clinical data, 22.22% (6/
27) of patientswho usedBiceraTM had their bone fusedwithin
3 months after the surgery, and66.67%(18/27) of patients had
their bone fused within 6 months. In a previous study, the
healing time of bone defects for TriositeTM was more than
6 months [14]. BiceraTM led to a relatively faster healing time
compared to that obtained with TriositeTM in the literature.
Pore size, structure, and porosity are factors influencing
osteoinductivity, which induces cell differentiation to achieve
osteogenesis [15, 16]. The higher porosity and more suit-
able pore size an interconnected pore structure has, the more
bone cell transforms into new bone tissue [17]. In addition, a
steady and gradual dissolution of BCP ceramics can help
create a localized environment rich in calciumandphosphorus
for osteogenic precursor cell adhesion, differentiation, pro-
duction of bone matrix, and finally, ossification. The fast and
sustained bone fusion observed in this study demonstrates that
the porousBCPbone substitute has sufficient osteoconduction
to help the fracture healing process.
Extensive animal and clinical studies have shown that
porous implants can result in ingrown bone and bone
regeneration [18–20]. Our animal study and clinical
observation showed new bone infiltrating into BiceraTM
12 weeks after the implantation. BiceraTM exhibited rela-
tively greater bone regeneration on the lateral femoral
condyle compared to that of the control group. BiceraTM
has interconnected pores with high porosity and induces
osteoconduction for new bone formation.
5 Conclusion
This study compared BCP bone substitutes. At 12 weeks
post-implantation in rabbits, BiceraTM and TriositeTM bone
substitutes had good incorporation with host bone, and new
bone formation infiltrated into the porous structure. In
clinical application, BiceraTM bone substitute has good
potential for the treatment of bone defects (e.g., commin-
uted fracture or arthrodesis).
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